-
Cluster globally, Reduce locally: Scalable efficient dictionary compression for magnetic resonance fingerprinting
Authors:
Geoffroy Oudoumanessah,
Thomas Coudert,
Luc Meyer,
Aurelien Delphin,
Michel Dojat,
Carole Lartizien,
Florence Forbes
Abstract:
With the rapid advancements in medical data acquisition and production, increasingly richer representations exist to characterize medical information. However, such large-scale data do not usually meet computing resource constraints or algorithmic complexity, and can only be processed after compression or reduction, at the potential loss of information. In this work, we consider specific Gaussian…
▽ More
With the rapid advancements in medical data acquisition and production, increasingly richer representations exist to characterize medical information. However, such large-scale data do not usually meet computing resource constraints or algorithmic complexity, and can only be processed after compression or reduction, at the potential loss of information. In this work, we consider specific Gaussian mixture models (HD-GMM), tailored to deal with high dimensional data and to limit information loss by providing component-specific lower dimensional representations. We also design an incremental algorithm to compute such representations for large data sets, overcoming hardware limitations of standard methods. Our procedure is illustrated in a magnetic resonance fingerprinting study, where it achieves a 97% dictionary compression for faster and more accurate map reconstructions.
△ Less
Submitted 11 November, 2024;
originally announced November 2024.
-
Design Considerations for a Phase II platform trial in Major Depressive Disorder
Authors:
Michaela Maria Freitag,
Dario Zocholl,
Elias Laurin Meyer,
Stefan M. Gold,
Marta Bofill Roig,
Heidi De Smedt,
Martin Posch,
Franz König
Abstract:
Major Depressive Disorder (MDD) is one of the most common causes of disability worldwide. Unfortunately, about one-third of patients do not benefit sufficiently from available treatments and not many new drugs have been developed in this area in recent years. We thus need better and faster ways to evaluate many different treatment options quickly. Platform trials are a possible remedy - they facil…
▽ More
Major Depressive Disorder (MDD) is one of the most common causes of disability worldwide. Unfortunately, about one-third of patients do not benefit sufficiently from available treatments and not many new drugs have been developed in this area in recent years. We thus need better and faster ways to evaluate many different treatment options quickly. Platform trials are a possible remedy - they facilitate the evaluation of more investigational treatments in a shorter period of time by sharing controls, as well as reducing clinical trial activation and recruitment times. We discuss design considerations for a platform trial in MDD, taking into account the unique disease characteristics, and present the results of extensive simulations to investigate the operating characteristics under various realistic scenarios. To allow the testing of more treatments, interim futility analyses should be performed to eliminate treatments that have either no or negligible treatment effect. Furthermore, we investigate different randomisation and allocation strategies as well as the impact of the per-treatment arm sample size. We compare the operating characteristics of such platform trials to those of traditional randomised controlled trials and highlight the potential advantages of platform trials.
△ Less
Submitted 3 October, 2023;
originally announced October 2023.
-
Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints
Authors:
Elias Laurin Meyer,
Peter Mesenbrink,
Nicholas A. Di Prospero,
Juan M. Pericàs,
Ekkehard Glimm,
Vlad Ratziu,
Elena Sena,
Franz König
Abstract:
Non-alcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and a disease with high unmet medical need. Platform trials provide great benefits for sponsors and trial participants in terms of accelerating drug development programs. In this article, we describe some of the activities of the EU-PEARL consortium (EU Patient-cEntric clinicAl tRial pLatforms)…
▽ More
Non-alcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and a disease with high unmet medical need. Platform trials provide great benefits for sponsors and trial participants in terms of accelerating drug development programs. In this article, we describe some of the activities of the EU-PEARL consortium (EU Patient-cEntric clinicAl tRial pLatforms) regarding the use of platform trials in NASH, in particular the proposed trial design, decision rules and simulation results. For a set of assumptions, we present the results of a simulation study recently discussed with two health authorities and the learnings from these meetings from a trial design perspective. Since the proposed design uses co-primary binary endpoints, we furthermore discuss the different options and practical considerations for simulating correlated binary endpoints.
△ Less
Submitted 11 January, 2023; v1 submitted 12 October, 2022;
originally announced October 2022.
-
CohortPlat: Simulation of cohort platform trials investigating combination therapies
Authors:
Elias Laurin Meyer,
Peter Mesenbrink,
Cornelia Dunger-Baldauf,
Ekkehard Glimm,
Franz König
Abstract:
Platform trials have gained a lot of attention recently as a possible remedy for time-consuming classical two-arm randomized controlled trials, especially in early phase drug development. This short article illustrates how to use the CohortPlat R package to simulate a cohort platform trial, where each cohort consists of a combination treatment and the respective monotherapies and standard-of-care.…
▽ More
Platform trials have gained a lot of attention recently as a possible remedy for time-consuming classical two-arm randomized controlled trials, especially in early phase drug development. This short article illustrates how to use the CohortPlat R package to simulate a cohort platform trial, where each cohort consists of a combination treatment and the respective monotherapies and standard-of-care. The endpoint is always assumed to be binary. The package offers extensive flexibility with respect to both platform trial trajectories, as well as treatment effect scenarios and decision rules. As a special feature, the package provides a designated function for running multiple such simulations efficiently in parallel and saving the results in a concise manner. Many illustrations of code usage are provided.
△ Less
Submitted 4 February, 2022;
originally announced February 2022.
-
Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials
Authors:
Elias Laurin Meyer,
Peter Mesenbrink,
Cornelia Dunger-Baldauf,
Ekkehard Glimm,
Yuhan Li,
Franz König
Abstract:
Platform trials have become increasingly popular for drug development programs, attracting interest from statisticians, clinicians and regulatory agencies. Many statistical questions related to designing platform trials - such as the impact of decision rules, sharing of information across cohorts, and allocation ratios on operating characteristics and error rates - remain unanswered. In many platf…
▽ More
Platform trials have become increasingly popular for drug development programs, attracting interest from statisticians, clinicians and regulatory agencies. Many statistical questions related to designing platform trials - such as the impact of decision rules, sharing of information across cohorts, and allocation ratios on operating characteristics and error rates - remain unanswered. In many platform trials, the definition of error rates is not straightforward as classical error rate concepts are not applicable. For an open-entry, exploratory platform trial design comparing combination therapies to the respective monotherapies and standard-of-care, we define a set of error rates and operating characteristics and then use these to compare a set of design parameters under a range of simulation assumptions. When setting up the simulations, we aimed for realistic trial trajectories, such that e.g. a priori we do not know the exact number of treatments that will be included over time in a specific simulation run as this follows a stochastic mechanism. Our results indicate that the method of data sharing, exact specification of decision rules and a priori assumptions regarding the treatment efficacy all strongly contribute to the operating characteristics of the platform trial. Furthermore, different operating characteristics might be of importance to different stakeholders. Together with the potential flexibility and complexity of a platform trial, which also impact the achieved operating characteristics via e.g. the degree of efficiency of data sharing, this implies that utmost care needs to be given to evaluation of different assumptions and design parameters at the design stage.
△ Less
Submitted 29 October, 2021; v1 submitted 17 March, 2021;
originally announced March 2021.
-
Uncertainty aware audiovisual activity recognition using deep Bayesian variational inference
Authors:
Mahesh Subedar,
Ranganath Krishnan,
Paulo Lopez Meyer,
Omesh Tickoo,
Jonathan Huang
Abstract:
Deep neural networks (DNNs) provide state-of-the-art results for a multitude of applications, but the approaches using DNNs for multimodal audiovisual applications do not consider predictive uncertainty associated with individual modalities. Bayesian deep learning methods provide principled confidence and quantify predictive uncertainty. Our contribution in this work is to propose an uncertainty a…
▽ More
Deep neural networks (DNNs) provide state-of-the-art results for a multitude of applications, but the approaches using DNNs for multimodal audiovisual applications do not consider predictive uncertainty associated with individual modalities. Bayesian deep learning methods provide principled confidence and quantify predictive uncertainty. Our contribution in this work is to propose an uncertainty aware multimodal Bayesian fusion framework for activity recognition. We demonstrate a novel approach that combines deterministic and variational layers to scale Bayesian DNNs to deeper architectures. Our experiments using in- and out-of-distribution samples selected from a subset of Moments-in-Time (MiT) dataset show a more reliable confidence measure as compared to the non-Bayesian baseline and the Monte Carlo dropout (MC dropout) approximate Bayesian inference. We also demonstrate the uncertainty estimates obtained from the proposed framework can identify out-of-distribution data on the UCF101 and MiT datasets. In the multimodal setting, the proposed framework improved precision-recall AUC by 10.2% on the subset of MiT dataset as compared to non-Bayesian baseline.
△ Less
Submitted 20 September, 2019; v1 submitted 26 November, 2018;
originally announced November 2018.
